Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.
This sBLA submission is supported by clinical, pre-clinical, and manufacturing data demonstrating the safety, tolerability, and immunogenicity of the bivalent vaccine.
Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
N-nitroso dimethylamine (NDMA) is a probable human carcinogen and tts effects on humans rely on observational studies.
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
Becomes the 1st diagnostics company in India to launch BD MAX MDR TB test
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Cipla has received 8 inspectional observations in Form 483
There is a fast resurgence in the transplant activities post COVID
Subscribe To Our Newsletter & Stay Updated
